SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
UC Biomed Building Investment: Advancing Research at the University of Coimbra
The Universidade de Coimbra (UC) is preparing to inaugurate its new UC Biomed building in the coming months, marking a significant milestone for the institution's biomedical research and teaching capabilities. According to recent updates, the facility—located at Polo III—has entered its final pha...
Overview of the Health Innovation Award 2026: Promoting Sustainable Solutions in Healthcare
The Health Innovation Award continues its mission in 2026 by spotlighting data-driven projects that advance sustainability across Portugal’s health sector. Launched by Faculdade de Medicina da Universidade de Lisboa, Sanofi, and NTT DATA Portugal, it invites submissions through its dedicated plat...
European Health Resilience: Strengthening Preparedness Amidst Geopolitical Challenges
EFPIA and Vaccines Europe endorse the European Commission’s Communication titled “Reinforcing Global Health Resilience Amidst Geopolitical Change,” published on 13 May, as a constructive advancement in bolstering European Health Resilience within a fragmented global environment. The statement hig...